1978 1980 1981 1982 1983 1984

1985 1986 1987 1988 1989 1990

1992 1993 1994 1995 1996 1997

1998 1999 2000 2001 2002 2003

2004 2005 2006 2007 2008

Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma.
Bostwick DG, Dousa MK, Crawford BG, Wollan PC.

Grading prostate cancer.
Bostwick DG.

Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer.
Bostwick DG.

Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate.
Bostwick DG, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, Humphrey P, Grignon D, Jones EC, et al.

c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: mounting evidence for a precursor role.
Bostwick DG.

Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
Bostwick DG.

Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography.
Gierke CL, King BF, Bostwick DG, Choyke PL, Hattery RR.

Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate.
Bostwick DG, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, Humphrey P, Grignon D, Jones EC, et al.

Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG.

Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies.
Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB.

Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE.

CT of Erdheim-Chester disease presenting as retroperitoneal xanthogranulomatosis.
Chiang KS, Larson TS, Swee RG, Bostwick DG, LeRoy AH.

Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.
Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE.

prostatic xanthoma: a mimic of prostatic adenocarcinoma.
Sebo TJ, Bostwick DG, Farrow GM, Eble JN.

Establishment of the formalin-free surgical pathology laboratory. Utility of an alcohol-based fixative.
Bostwick DG, al Annouf N, Choi C.

Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases.
Adlakha H, Bostwick DG.

Current and proposed biologic markers in prostate cancer: 1994.
Bostwick DG, Qian J.

Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG.

The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, et al.

Staging of prostate cancer.
Bostwick DG, Myers RP, Oesterling JE.